Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/29360

TitlePrognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation : a Portuguese multicentre study
Author(s)Costa, Bruno Marques
Caeiro, Cláudia
Guimarães, Inês
Martinho, Olga
Jaraquemada, Teresa
Augusto, Isabel
Castro, Lígia
Osório, Lígia
Linhares, Paulo
Honavar, Mrinalini
Resende, Mário
Braga, Fátima
Silva, Ana
Pardal, Fernando
Amorim, Júlia
Nabiço, Rui
Almeida, Rui
Alegria, Carlos
Pires, Manuel
Pinheiro, Célia
Carvalho, Ernesto
Lopes, José M.
Costa, Paulo
Damasceno, Margarida
Reis, R. M.
KeywordsGlioblastoma
Prognosis
MGMT methylation
Temozolomide
Chemoradiation
Issue date2010
PublisherSpandidos Publications
JournalOncology Reports
Abstract(s)Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol). The Kaplan-Meier method was used to construct survival curves, and the log-rank test and a Cox-regression model were used to analyze patient survival. The methylation status of MGMT was successfully determined in 89% (80/90) of the tumors. The frequency of tumoral MGMT promoter methylation was 47.5%. The median overall survivals (OSs) were 16 months (95% CI 12.2-19.8) and 13 months (95% CI 13.3-18.7) for patients whose tumors had a methylated or unmethylated MGMT, respectively. Univariate and multivariate analyses did not show any statistically significant association between MGMT methylation status and patient OS (P=0.583 by the log-rank test; P=0.617 by the Cox-regression test) or progression-free survival (P=0.775 by the log-rank test; P=0.691 by the Cox-regression test). None of the patient clinical features were significantly correlated with survival. This is the first study to report the frequency of MGMT methylation among Portuguese GBM patients. Our data did not show statistically significant associations between MGMT promoter methylation and the outcome of GBM patients treated with temozolomide. Additional robust prospective studies are warranted to clarify whether the MGMT status should be used in clinical decisions.
TypeArticle
URIhttp://hdl.handle.net/1822/29360
DOI10.3892/or_00000808
ISSN1021-335X
1791-2431
Publisher versionhttp://www.spandidos-publications.com/or/23/6/1655
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
costa bm_ oncol rep 2010.pdf123,85 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID